Compounds > 2-acetylbenzothiophene
Page last updated: 2024-12-07

2-acetylbenzothiophene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-acetylbenzothiophene: metabolite of zileuton; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID89805
CHEMBL ID541695
SCHEMBL ID407602
MeSH IDM0473736

Synonyms (47)

Synonym
2-acetylbenzo[b]thiophene ,
2-acetylbenzothiophene, 97%
2-acetylbenzothiophene
AKOS000280479
22720-75-8
CHEMBL541695
sgsgcqgcvkwrnm-uhfffaoysa-
inchi=1/c10h8os/c1-7(11)10-6-8-4-2-3-5-9(8)12-10/h2-6h,1h3
1-(1-benzothiophen-2-yl)ethanone
1-(benzo[b]thiophen-2-yl)ethanone
A4849
1-(benzo[b]thiophen-2-yl)-ethanone
1-benzo[b]thiophen-2-yl-ethanone
zc5epe32df ,
1-benzo(b)thien-2-ylethan-1-one
einecs 245-177-7
ethanone, 1-benzo(b)thien-2-yl-
unii-zc5epe32df
ethanone, 1-benzo[b]thienyl-
FT-0610970
FS-2177
SCHEMBL407602
1-(1-benzothiophen-2-yl)ethan-1-one
tox21_113819
dtxcid4031481
cas-22720-75-8
NCGC00253698-01
dtxsid3057692 ,
mfcd00090217
SY001822
2-acetyl benzo[b]thiophene
SGSGCQGCVKWRNM-UHFFFAOYSA-N
1-(benzo[b]thiophen-2-yl)ethan-1-one
1-(benzo[b]thiophen-2-yl]ethan-1-one
2-acetylbenzothiophen
W-107460
AC-24592
F1905-7187
CS-D0712
SR-01000944859-1
sr-01000944859
1-benzo-[b]thien-2-ylethanone
1-benzo-[b]thien-2-ylethanone; zileuton related compound c
AMY23205
2-acetyl benzothiophene
EN300-157748
Z337709350

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The in vitro and in vivo data presented here demonstrate the formation of 2-ABT from zileuton and its further bioactivation to a potentially toxic metabolite."( In vitro metabolism of 2-acetylbenzothiophene: relevance to zileuton hepatotoxicity.
Chordia, MD; Heasley, BH; Joshi, EM; Macdonald, TL, 2004)		0.63

Dosage Studied

ExcerptRelevanceReference
" LC/MS analyses of urine samples collected from rats dosed with zileuton indicate that C1 is a metabolite of zileuton formed in vivo."( In vitro metabolism of 2-acetylbenzothiophene: relevance to zileuton hepatotoxicity.
Chordia, MD; Heasley, BH; Joshi, EM; Macdonald, TL, 2004)		0.63
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency33.49150.001022.650876.6163AID1224838; AID1224893
Histone H2A.xCricetulus griseus (Chinese hamster)Potency31.03930.039147.5451146.8240AID1224845
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (153)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1739434Metabolic stability in human liver microsomes assessed as intrinsic clearance at 100 uM measured per mg protein upto 30 mins2020European journal of medicinal chemistry, Aug-15, Volume: 200Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
AID430560Antiosteoporotic activity in po dosed ovariectomized Sprague-Dawley rat assessed as mineral apposition rate administered for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID1202366Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as alanine transaminase level at 30 mg/kg/day, po administered six times a week for 3 months (Rvb = 43.73 +/- 36.21 U/L)2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID476541Toxicity in SAMP6 mouse assessed as pathological changes in liver at 30 mg/kg/day, po after 3 months by histomorphology2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID476549Toxicity in rat assessed as pathological changes in spleen at 150 mg/kg/day, po after 3 months by histomorphology2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID476533Induction of bone formation in ovariectomized rat assessed as increase in trabecular bone volume percentage at 7.5 mg/kg/day, po after 3 months2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID1202343Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as white blood cells at 30 mg/kg/day, po administered six times a week for 3 months (Rvb = 6.28 +/- 2.78 x 10'9/L)2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID1202372Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as effect on total protein level at 30 mg/kg/day, po administered six times a week for 3 months2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID430530Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as osteo cortex mineralization rate at 30 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID430547Toxicity in sham operated Sprague-Dawley rat assessed as effect on triglycerides level at 150 mg/kg/day, po for 90 days2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID476546Toxicity in SAMP6 mouse assessed as change in 24 hrs food consumption at 30 mg/kg/day, po after 3 months2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID430557Antiosteoporotic activity in po dosed ovariectomized Sprague-Dawley rat assessed as trabecular bone volume administered for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID476512Induction of BMP2 expression in mouse calcarial MC3T3-E1 cells stably transfected with mouse BMP2 promotor-luciferase assessed as upregulation rate at 4 uM2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID430553Toxicity in sham operated Sprague-Dawley rat assessed as effect on creatinine level at 150 mg/kg/day, po for 90 days2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID430495Enhancement of BMP-2 expression in mouse MC3T3-E1 cells assessed as upregulation rate at 4 uM2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID1202352Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as effect on red blood cells at 30 mg/kg/day, po administered six times a week for 3 months2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID476535Induction of bone formation in ovariectomized rat assessed as increase in trabecular bone volume percentage at 30 mg/kg/day, po after 3 months2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID476540Toxicity in SAMP6 mouse assessed as pathological changes in spleen at 30 mg/kg/day, po after 3 months by histomorphology2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID1202357Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as effect on red blood cell distribution width at 30 mg/kg/day, po administered six times a week for 3 months2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID1202373Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as effect on albumin level at 30 mg/kg/day, po administered six times a week for 3 months2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID476552Toxicity in rat assessed as pathological changes in kidney at 150 mg/kg/day, po after 3 months by histomorphology2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID476509Induction of bone mineral density in SAMP6 mouse assessed as whole body BMD at 10 mg/kg/day, po measured after 2 months2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID1202402Antiosteoporotic activity in glucocorticoid-induced Wistar rat osteoporosis model assessed as trabecula resorption surface at 30 mg/kg/day, po administered six times a week for 3 months by fluorescence assay (Rvb = 7.22 +/- 2.04%)2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID430529Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as osteo cortex mineralization rate at 15 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID1739425Antiosteoporotic activity in Sprague-Dawley rat model of OVX-induced bone loss assessed as increase in trabecular bone mineral density at 30 mg/kg, ig administered for 3 months with 1 day break after 6 consecutive days administration2020European journal of medicinal chemistry, Aug-15, Volume: 200Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
AID476534Induction of bone formation in ovariectomized rat assessed as increase in trabecular bone volume percentage at 15 mg/kg/day, po after 3 months2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID430538Toxicity in po dosed Kunming mouse2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID1739421Antiosteoporotic activity in Sprague-Dawley rat model of OVX-induced bone loss assessed as increase in number of trabeculae at 30 mg/kg, ig administered for 3 months with 1 day break after 6 consecutive days administration2020European journal of medicinal chemistry, Aug-15, Volume: 200Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
AID430554Toxicity in sham operated Sprague-Dawley rat assessed as effect on calcium level at 150 mg/kg/day, po for 90 days2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID430502Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as trabecular bone volume at 30 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID430543Toxicity in sham operated Sprague-Dawley rat assessed as effect on total bilirubin level at 150 mg/kg/day, po for 90 days2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID476525Induction of BMP2 expression in SAMP6 mouse osteoblast at 10 mg/kg/day, po after 3 months by immunohistochemical analysis2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID476551Toxicity in rat assessed as pathological changes in lung at 150 mg/kg/day, po after 3 months by histomorphology2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID476523Induction of bone formation in SAMP6 mouse right femora assessed as trabecular resorption surface percentage at 30 mg/kg/day, po measured after 3 months by bone histomorphometry2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID430516Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as trabecula formation surface at 30 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID430558Antiosteoporotic activity in po dosed ovariectomized Sprague-Dawley rat assessed as trabecula formation surface administered for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID430550Toxicity in sham operated Sprague-Dawley rat assessed as effect on direct-low density lipoprotein level at 150 mg/kg/day, po for 90 days2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID430507Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as trabecula resorption surface at 7.5 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID1202388Antiosteoporotic activity in glucocorticoid-induced Wistar rat osteoporosis model assessed as increase in trabecula connectivity at 30 mg/kg/day, po administered six times a week for 3 months by toluidine blue staining-based light microscopic analysis rel2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID476515Induction of bone mineral density in SAMP6 mouse assessed as spine BMD at 30 mg/kg/day, po measured after 3 months2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID1202376Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as effect on glucose level at 30 mg/kg/day, po administered six times a week for 3 months2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID476530Induction of BMP2 expression in SAMP6 mouse cartilage cells at 30 mg/kg/day, po after 3 months by immunohistochemical analysis2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID1739422Antiosteoporotic activity in Sprague-Dawley rat model of OVX-induced bone loss assessed as increase in thickness of trabeculae at 30 mg/kg, ig administered for 3 months with 1 day break after 6 consecutive days administration2020European journal of medicinal chemistry, Aug-15, Volume: 200Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
AID430559Antiosteoporotic activity in po dosed ovariectomized Sprague-Dawley rat assessed as trabecula resorption surface administered for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID430551Toxicity in sham operated Sprague-Dawley rat assessed as effect on glucose level at 150 mg/kg/day, po for 90 days2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID1202362Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as aspartate transaminase level at 30 mg/kg/day, po administered six times a week for 3 months (Rvb = 177.55 +/- 116.98 U/L)2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID430528Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as osteo cortex mineralization rate at 7.5 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID476521Induction of bone formation in SAMP6 mouse right femora assessed as trabecular bone volume percentage at 30 mg/kg/day, po measured after 3 months by bone histomorphometry2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID476536Induction of bone formation in ovariectomized rat assessed as decrease in trabecular resorption surface percentage at 7.5 mg/kg/day, po after 3 months2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID1202394Antiosteoporotic activity in glucocorticoid-induced Wistar rat osteoporosis model assessed as trabecular bone volume at 30 mg/kg/day, po administered six times a week for 3 months by fluorescence assay (Rvb = 33.09 +/- 5.15%)2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID1202406Antiosteoporotic activity in glucocorticoid-induced Wistar rat osteoporosis model assessed as mineral apposition rate at 30 mg/kg/day, po administered six times a week for 3 months by fluorescence assay (Rvb = 1.06 +/- 0.27 micrometer/day)2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID430535Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as average osteoid width at 7.5 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID476538Induction of bone formation in ovariectomized rat assessed as decrease in trabecular resorption surface percentage at 30 mg/kg/day, po after 3 months2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID430552Toxicity in sham operated Sprague-Dawley rat assessed as effect on blood urea nitrogen level at 150 mg/kg/day, po for 90 days2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID476505Induction of bone mineral density in SAMP6 mouse assessed as spine BMD at 30 mg/kg/day, po measured first 2 months2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID1202385Antiosteoporotic activity in glucocorticoid-induced Wistar rat osteoporosis model assessed as increase in trabecula number at 30 mg/kg/day, po administered six times a week for 3 months by toluidine blue staining-based light microscopic analysis relative 2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID430522Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as mineral apposition rate at 15 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID1202347Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as lymph level at 30 mg/kg/day, po administered six times a week for 3 months (Rvb = 50.35 +/- 12.96%)2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID476537Induction of bone formation in ovariectomized rat assessed as decrease in trabecular resorption surface percentage at 15 mg/kg/day, po after 3 months2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID476554Toxicity in ip dosed Kunming mouse assessed as mortality treated for 3 days measured after 17 days2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID476532Prevention of bone loss in po dosed ovariectomized rat assessed as increase in number, thickness, area and connectivity of trabecula after 3 months by histomorphometry Leica Qwin image analysis2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID476553Toxicity in rat assessed as pathological increase in body weight at 150 mg/kg/day, po after 3 months2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID476531Prevention of bone loss in ovariectomized rat assessed as increase in number, thickness, area and connectivity of trabecula at 30 mg/kg/day, po after 3 months by histomorphometry Leica Qwin image analysis2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID476510Induction of bone mineral density in SAMP6 mouse assessed as whole body BMD at 10 mg/kg/day, po measured after 1 month2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID430555Toxicity in sham operated Sprague-Dawley rat assessed as effect on bone histomorphometric parameters at 150 mg/kg/day, po for 90 days2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID430514Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as trabecula formation surface at 7.5 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID1202353Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as effect on hemoglobin at 30 mg/kg/day, po administered six times a week for 3 months2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID476539Toxicity in SAMP6 mouse assessed as pathological changes in heart at 30 mg/kg/day, po after 3 months by histomorphology2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID476548Toxicity in rat assessed as pathological changes in heart at 150 mg/kg/day, po after 3 months by histomorphology2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID430549Toxicity in sham operated Sprague-Dawley rat assessed as effect on direct-high density lipoprotein level at 150 mg/kg/day, po for 90 days2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID430545Toxicity in sham operated Sprague-Dawley rat assessed as effect on total protein level at 150 mg/kg/day, po for 90 days2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID430546Toxicity in sham operated Sprague-Dawley rat assessed as effect on albumin level at 150 mg/kg/day, po for 90 days2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID430509Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as trabecula resorption surface at 30 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID430544Toxicity in sham operated Sprague-Dawley rat assessed as effect on alkaline phosphatase level at 150 mg/kg/day, po for 90 days2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID476529Induction of BMP2 expression in SAMP6 mouse cartilage cells at 10 mg/kg/day, po after 3 months by immunohistochemical analysis2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID476516Induction of bone mineral density in SAMP6 mouse assessed as left hind leg BMD at 30 mg/kg/day, po measured after 3 months2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID1202386Antiosteoporotic activity in glucocorticoid-induced Wistar rat osteoporosis model assessed as increase in trabecula thickness at 30 mg/kg/day, po administered six times a week for 3 months by toluidine blue staining-based light microscopic analysis relati2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID430515Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as trabecula formation surface at 15 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID1202351Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as neutrophilic granulocytes level at 30 mg/kg/day, po administered six times a week for 3 months (Rvb = 31.95 +/- 8.33%)2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID430537Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as average osteoid width at 30 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID1202374Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as effect on blood urea nitrogen level at 30 mg/kg/day, po administered six times a week for 3 months2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID476527Induction of BMP2 expression in SAMP6 mouse bone marrow stroma at 10 mg/kg/day, po after 3 months by immunohistochemical analysis2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID476542Toxicity in SAMP6 mouse assessed as pathological changes in lung at 30 mg/kg/day, po after 3 months by histomorphology2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID430542Toxicity in sham operated Sprague-Dawley rat assessed as effect on glutamic-pyruvic transaminase level at 150 mg/kg/day, po for 90 days2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID430562Antiosteoporotic activity in po dosed ovariectomized Sprague-Dawley rat assessed as average osteoid width administered for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID476502Prevention of bone loss in ovariectomized rat assessed as increase in number, thickness, area and connectivity of trabecula at 15 mg/kg/day, po after 3 months by histomorphometry Leica Qwin image analysis2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID430539Toxicity in ip dosed Kunming mouse2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID430536Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as average osteoid width at 15 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID1202358Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as effect on platelets at 30 mg/kg/day, po administered six times a week for 3 months2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID1202354Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as effect on red blood cell specific volume at 30 mg/kg/day, po administered six times a week for 3 months2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID476545Toxicity in SAMP6 mouse assessed as change in 24 hrs water consumption at 30 mg/kg/day, po after 3 months2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID476526Induction of BMP2 expression in SAMP6 mouse osteoblast at 30 mg/kg/day, po after 3 months by immunohistochemical analysis2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID430521Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as mineral apposition rate at 7.5 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID476524Induction of bone formation in SAMP6 mouse right femora assessed as average osteoid width at 30 mg/kg/day, po measured after 3 months by bone histomorphometry2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID1739424Antiosteoporotic activity in Sprague-Dawley rat model of OVX-induced bone loss assessed as increase in trabecular bone volume at 30 mg/kg, ig administered for 3 months with 1 day break after 6 consecutive days administration2020European journal of medicinal chemistry, Aug-15, Volume: 200Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
AID430540Toxicity in sham operated Sprague-Dawley rat assessed as effect on general behavior at 150 mg/kg/day, po for 90 days2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID430541Toxicity in sham operated Sprague-Dawley rat assessed as effect on glutamine-oxaloacetic transaminase level at 150 mg/kg/day, po for 90 days2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID476528Induction of BMP2 expression in SAMP6 mouse bone marrow stroma at 30 mg/kg/day, po after 3 months by immunohistochemical analysis2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID1739433Metabolic stability in human liver microsomes assessed as half life at 100 uM measured upto 30 mins2020European journal of medicinal chemistry, Aug-15, Volume: 200Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
AID1739432Permeability across apical to basolateral side in human Caco-2 cells assessed as luciferase yellow leakage at 10 uM incubated for 2 hrs LC-MS/MS analysis2020European journal of medicinal chemistry, Aug-15, Volume: 200Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
AID476514Induction of bone mineral density in SAMP6 mouse assessed as whole body BMD at 30 mg/kg/day, po measured after 3 months2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID1739430Apparent permeability across apical to basolateral side in human Caco-2 cells at 10 uM incubated for 2 hrs LC-MS/MS analysis2020European journal of medicinal chemistry, Aug-15, Volume: 200Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
AID430548Toxicity in sham operated Sprague-Dawley rat assessed as effect on total cholesterol level at 150 mg/kg/day, po for 90 days2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID430508Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as trabecula resorption surface at 15 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID1202370Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as triglycerides level at 30 mg/kg/day, po administered six times a week for 3 months (Rvb = 1.13 +/- 0.69 mmol/L)2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID430501Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as trabecular bone volume at 15 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID1202375Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as effect on creatinine level at 30 mg/kg/day, po administered six times a week for 3 months2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID430561Antiosteoporotic activity in po dosed ovariectomized Sprague-Dawley rat assessed as osteo cortex mineralization rate administered for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID1202387Antiosteoporotic activity in glucocorticoid-induced Wistar rat osteoporosis model assessed as increase in trabecula area at 30 mg/kg/day, po administered six times a week for 3 months by toluidine blue staining-based light microscopic analysis relative to2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID476522Induction of bone formation in SAMP6 mouse right femora assessed as trabecular formation surface percentage at 30 mg/kg/day, po measured after 3 months by bone histomorphometry2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID1739431Permeability across apical to basolateral side in human Caco-2 cells assessed as transepithelial electrical resistance at 10 uM incubated for 2 hrs LC-MS/MS analysis2020European journal of medicinal chemistry, Aug-15, Volume: 200Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
AID1202355Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as effect on mean corpuscular volume at 30 mg/kg/day, po administered six times a week for 3 months2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID430500Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as trabecular bone volume at 7.5 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID1202398Antiosteoporotic activity in glucocorticoid-induced Wistar rat osteoporosis model assessed as trabecula formation surface at 30 mg/kg/day, po administered six times a week for 3 months by fluorescence assay (Rvb = 7.82 +/- 2.46%)2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID1202371Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as effect on total bilirubin level at 30 mg/kg/day, po administered six times a week for 3 months2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID1202356Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as effect on mean corpuscular hemoglobin concentration at 30 mg/kg/day, po administered six times a week for 3 months2015European journal of medicinal chemistry, , Volume: 96Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats.
AID476550Toxicity in rat assessed as pathological changes in liver at 150 mg/kg/day, po after 3 months by histomorphology2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID476544Toxicity in SAMP6 mouse assessed as increase in body weight at 30 mg/kg/day, po after 3 months2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID430523Antiosteoporotic activity in ovariectomized Sprague-Dawley rat assessed as mineral apposition rate at 30 mg/kg/day, po for 90 days by bone histomorphometry2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID476547Toxicity in po dosed Kunming mouse assessed as mortality treated for 3 days measured after 17 days2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
AID1739423Antiosteoporotic activity in Sprague-Dawley rat model of OVX-induced bone loss assessed as narrowed gap between trabeculae at 30 mg/kg, ig administered for 3 months with 1 day break after 6 consecutive days administration2020European journal of medicinal chemistry, Aug-15, Volume: 200Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
AID476543Toxicity in SAMP6 mouse assessed as pathological changes in kidney at 30 mg/kg/day, po after 3 months by histomorphology2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (15.38)29.6817
2010's4 (30.77)24.3611
2020's7 (53.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.25 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.89 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		2.2510aromatic ether;
nitrile;
polyether;
tertiary amino compound
cimetidine
Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.		2.2510aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
diclofenac
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.		2.2510amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
hydroxyurea
[no description available]		2.0210one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
imipramine
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.		2.2510dibenzoazepineadrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
metoprolol
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.. metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.		2.2510aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound		antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic
phenacetin
Saridon: contains phenacetin, caffeine, propyphenazone & pyrithyldione		2.2510acetamides;
aromatic ether		cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug
raloxifene
raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.		2.8301-benzothiophenes;
aromatic ketone;
N-oxyethylpiperidine;
phenols		bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
sulfaphenazole
Sulfaphenazole: A sulfonilamide anti-infective agent.. sulfaphenazole : A sulfonamide that is sulfanilamide in which the sulfonamide nitrogen is substituted by a 1-phenyl-1H-pyrazol-5-yl group. It is a selective inhibitor of cytochrome P450 (CYP) 2C9 isozyme, and antibacterial agent.		2.2510primary amino compound;
pyrazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor;
P450 inhibitor
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		2.0210mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
alpha-naphthoflavone
alpha-naphthoflavone: inhibits P4501A1 and P4501A2; stimulates some activities of P4503A4. alpha-naphthoflavone : An extended flavonoid resulting from the formal fusion of a benzene ring with the h side of flavone. A synthetic compound, it is an inhibitor of aromatase (EC 1.14.14.14).		2.2510extended flavonoid;
naphtho-gamma-pyrone;
organic heterotricyclic compound		aryl hydrocarbon receptor agonist;
aryl hydrocarbon receptor antagonist;
EC 1.14.14.14 (aromatase) inhibitor
benzydamine
Benzydamine: A benzyl-indazole having analgesic, antipyretic, and anti-inflammatory effects. It is used to reduce post-surgical and post-traumatic pain and edema and to promote healing. It is also used topically in treatment of RHEUMATIC DISEASES and INFLAMMATION of the mouth and throat.. benzydamine : A member of the class of indazoles carrying benzyl and 3-(dimethylamino)propyl groups at positions 1 and 3 respectively. A locally-acting nonsteroidal anti-inflammatory drug that also exhibits local anaesthetic and analgesic properties.		2.2510aromatic ether;
indazoles;
tertiary amino compound		analgesic;
central nervous system stimulant;
hallucinogen;
local anaesthetic;
non-steroidal anti-inflammatory drug
erythromycin
Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.		2.2510cyclic ketone;
erythromycin
3-acetylindole
3-acetylindole: structure in first source		2.0510
2-acetylbenzofuran
2-acetylbenzofuran: structure in first source		2.4620
tranylcypromine
Tranylcypromine: A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311). tranylcypromine : A racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).. (1R,2S)-tranylcypromine : A 2-phenylcyclopropan-1-amine that is the (1R,2S)-enantiomer of tranylcypromine.		2.25102-phenylcyclopropan-1-amine
lovastatin
Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).		3.0140delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug
zileuton
[no description available]		7.02101-benzothiophenes;
ureas		anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug
benzo(b)thiophene-2-carboxylic acid
benzo(b)thiophene-2-carboxylic acid: for prevention of osteoporosis; structure given in first source		2.0510
quinidine
Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.		2.2510cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
ketoconazole
(2R,4S)-ketoconazole : A cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2R,4S)-configuration.		2.2510cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
ConditionIndicatedRelationship StrengthStudiesTrials
Age-Related Osteoporosis
[description not available]		03.0140
Osteoporosis
Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.		03.0140
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.6620
Congenital Zika Syndrome
[description not available]		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510